Key regions: Japan, India, Italy, Brazil, South Korea
The demand for Anti-Hypertensive Drugs in Russia has been increasing steadily over the years.
Customer preferences: The primary reason for the growing demand for Anti-Hypertensive Drugs in Russia is the rising prevalence of hypertension among the population. According to a survey conducted by the Russian Public Opinion Research Center, around 30% of the adult population in Russia suffers from hypertension. This has led to an increase in demand for Anti-Hypertensive Drugs, as they are the most effective way to manage and control hypertension.
Trends in the market: The Anti-Hypertensive Drugs market in Russia is dominated by a few major players, such as Pfizer, Novartis, and Sanofi. These companies have a strong presence in the country and offer a wide range of Anti-Hypertensive Drugs. The market is also witnessing an increase in the number of generic drugs, which are more affordable and accessible to the general population.
Local special circumstances: One of the unique features of the Russian market is the dominance of state-owned pharmacies. The state-owned pharmacies account for a significant portion of the overall pharmaceutical market in Russia. This has led to a situation where the prices of drugs are heavily regulated by the government. As a result, the prices of Anti-Hypertensive Drugs in Russia are relatively low compared to other countries.
Underlying macroeconomic factors: The Russian economy has been recovering from the recession of 2014-2015. The GDP growth rate has been positive, and the unemployment rate has been declining. This has led to an increase in disposable income among the population, which has further fueled the demand for Anti-Hypertensive Drugs. The government has also been investing heavily in the healthcare sector, which has led to an improvement in the overall healthcare infrastructure in the country. This has further increased the accessibility of Anti-Hypertensive Drugs to the general population.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
